Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ATP-sensitive potassium channel (K_ATP channel) in pancreatic beta cells regulates insulin secretion in response to blood glucose levels. It is a hetero-octamer comprised of four pore-forming Kir6.2 subunits and four regulatory SUR1 subunits. Sulfonylurea drugs treat type 2 diabetes by binding to SUR1, causing channel closure, cell membrane depolarization, calcium influx, and subsequent insulin secretion. Prolonged or excessive activation can lead to secondary drug failure or resistance, and the principal safety concern is increased risk of hypoglycemia, particularly in patients with fragile glycemic control[2][3][4][6][8]. This target is central to the pharmacological management of diabetes but is not a 'receptor' in the classical sense—instead, it is a drug-regulated ion channel complex.
Sulfonylureas bind to the SUR1 subunit, closing the K_ATP channel. - Channel closure depolarizes beta cell membrane. - Depolarization opens voltage-dependent calcium channels, causing Ca²⁺ influx. - Intracellular calcium triggers insulin granule exocytosis[2][3][4][6][8].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP-sensitive potassium channel, pancreatic beta cell type (K_ATP channel (beta cell)).